SURAKSHA DIAGNOSTIC LIMITED Share Price & Stock Analysis

SURAKSHA DIAGNOSTIC LIMITED (NSE: SURAKSHA, BSE: 544293) is a Kolkata, West Bengal-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹1,856 Cr, it ranks #1,281 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 18 in Medical Diagnostic Centres. At ₹340.50 (as of 16 Nov 2026), the share price is 11.3% below its 52-week high of ₹384.00 and 51.9% above its 52-week low of ₹224.10. The share price is up 6.9% over one year and up 12.2% over three months.

Key Metrics

Current Price₹340.50
Market Cap₹1,856 Cr
NSE SymbolSURAKSHA
BSE Code544293
SectorHealth Care > Health Care Equipment and Services > Health Care Providers and Services
Sub-IndustryHealth Care Services > Medical Diagnostic Centres
P/E Ratio55.4
Return on Equity13.84%
Return on Assets8.67%
52-Week Range₹224.10 – ₹384.00
1-Year Price Change+6.9%
3-Month Price Change+12.2%
Beta (1Y)0.46
Dividend Yield0.15%
HeadquartersKolkata, West Bengal
Websitewww.surakshanet.com

Latest Quarterly Results — Q2 FY27

Revenue₹99 Cr
Net Profit₹15 Cr
Net Margin15.1%
EPS (Basic)₹2.88
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

SURAKSHA DIAGNOSTIC LIMITED Quarterly Revenue and Profit Trend

SURAKSHA DIAGNOSTIC LIMITED reported revenue of ₹99 Cr in Q2 FY27, up 25.8% from ₹79 Cr in Q2 FY26 and up 13.0% from ₹88 Cr in Q1 FY27. It posted a net profit of ₹15 Cr for the quarter, against a net profit of ₹9 Cr in Q2 FY26 (up 69.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹65 Cr (Q4 FY25) to ₹99 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹99 Cr₹15 Cr15.1%
Q1 FY27₹88 Cr₹13 Cr14.7%
Q4 FY26₹81 Cr₹6 Cr7.6%
Q3 FY26₹78 Cr₹7 Cr9.3%
Q2 FY26₹79 Cr₹9 Cr11.2%
Q1 FY26₹73 Cr₹9 Cr12.6%
Q4 FY25₹65 Cr₹7 Cr11.0%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 49.10% of SURAKSHA DIAGNOSTIC LIMITED's shares as of Sept 2026, against 48.98% in Sept 2025 (+0.12 percentage points). Delivery averaged 48.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About SURAKSHA DIAGNOSTIC LIMITED

Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In

Products and Services

1. Diagnostic Centres for Carrying out Various Pathology and Radiology Services-This segment operates a chain of diagnostic centers that provide various pathology and radiology services. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Diagnostic Centres for Carrying out Various Pathology and Radiology Services-100%

SURAKSHA DIAGNOSTIC LIMITED vs Peers — Medical Diagnostic Centres

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Dr. Lal Pathlabs Ltd₹33,934 Cr66.421.48%₹874 Cr+28.7%
Vijaya Diagnostic Centre Limited₹14,665 Cr84.319.70%₹255 Cr+38.5%
Metropolis Healthcare Limited₹11,952 Cr61.513.37%₹497 Cr+14.9%
Throcare Technologies Ltd₹7,764 Cr47.628.74%₹271 Cr+7.5%
SURAKSHA DIAGNOSTIC LIMITED₹1,856 Cr55.413.84%₹99 Cr+6.9%
Krsnaa Diagnostics Ltd₹1,625 Cr16.810.89%₹271 Cr-27.0%
Gaudium IVF and Women Health Limited₹803 Cr27.416.08%₹37 Cr—
Chandan Healthcare Limited₹582 Cr21.918.43%₹81 Cr—
Aspira Pathlab & Diagnostics Ltd₹127 Cr2,360——+115.2%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of SURAKSHA DIAGNOSTIC LIMITED?

SURAKSHA DIAGNOSTIC LIMITED is trading at ₹340.50, with a market capitalisation of ₹1,856 Cr.

Which sector does SURAKSHA DIAGNOSTIC LIMITED belong to?

SURAKSHA DIAGNOSTIC LIMITED operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).

What are the key financial ratios of SURAKSHA DIAGNOSTIC LIMITED?

SURAKSHA DIAGNOSTIC LIMITED has a P/E of 55.4 and a return on equity of 13.84%.

What is the stock symbol of SURAKSHA DIAGNOSTIC LIMITED?

SURAKSHA DIAGNOSTIC LIMITED is listed on the NSE under the symbol SURAKSHA and on the BSE under the scrip code 544293.

How has SURAKSHA DIAGNOSTIC LIMITED's share price moved over the past year?

SURAKSHA DIAGNOSTIC LIMITED's share price is up 6.9% over one year and up 12.2% over three months. Its 52-week range is ₹224.10 to ₹384.00.

What were SURAKSHA DIAGNOSTIC LIMITED's latest quarterly results?

In Q2 FY27, SURAKSHA DIAGNOSTIC LIMITED reported revenue of ₹99 Cr and net profit of ₹15 Cr, with basic EPS of ₹2.88 (consolidated, parsed from the company's exchange filing).

How have SURAKSHA DIAGNOSTIC LIMITED's revenue and profit changed over the past year?

SURAKSHA DIAGNOSTIC LIMITED reported revenue of ₹99 Cr in Q2 FY27, up 25.8% from ₹79 Cr in Q2 FY26 and up 13.0% from ₹88 Cr in Q1 FY27.

What is the promoter holding in SURAKSHA DIAGNOSTIC LIMITED?

Promoters held 49.10% of SURAKSHA DIAGNOSTIC LIMITED's shares as of Sept 2026, against 48.98% in Sept 2025 (+0.12 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.